Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH-STROKE
NCT06269432Phase 4Completed
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel and ticagrelor in ischemic stroke (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Incidence of High On-treatment Platelet Reactivity at 1 month. Started Jan 2023; status: completed.
02
Drugs
clopidogrelticagrelor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06269432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269432.